NCT03853707: Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known brain metastasis or leptomeningeal metastasis from metastatic breast cancer- see trial for details

Comments are closed.

Up ↑